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Abstract. We investigated the Nco I restriction frag- 
ment length polymorphism (RFLP) of the tumor necro- 
sis factor beta (TNFB) gene in 173 patients with sys- 
temic lupus erythematosus (SLE), 192 unrelated 
healthy controls, and eleven panel families, all of Ger- 
man origin. The phenotype frequency of the TNFB*I 
allele was significantly increased in patients compared 
to controls (63.6% vs 47.1%, RR = 1.96, p <0.002). 
The results of a two-point haplotype statistical analysis 
between TNFB and HLA alleles show that there is link- 
age disequilibrium between TNFB*I and HLA-A1, 
Cw7, B8, DR3, DQ2, and C4A DE. The frequency of 
TNFB*I was compared in SLE patients and controls in 
the presence or absence of each of these alleles. 
TNFB*I is increased in patients over controls only in 
the presence of the mentioned alleles. Therefore, the 
whole haplotypeA1, Cw7, B8, TNFB* I, C4A DE, DR3, 
DQ2 is increased in patients and it cannot be deter- 
mined which of the genes carried by this haplotype is 
responsible for the susceptibility to SLE. In addition, 
two-locus associations were analyzed in 192 unrelated 
healthy controls for TNFB and class I alleles typed by 
serology, and for TNFB and class II alleles typed by 
polymerase chain reaction/oligonucleotide probes. We 
found positive linkage disequilibrium between 
TNFB*I and the following alleles: HLA-A24, HLA-B8, 
DRBI*0301, DRBI*ll04, DRBI*1302, DQAI*0501, 
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DQBI*0201, DQBI*0604, and DPBI*OIO1. TNFB*2 
is associated with HLA-B7, DRBI*1501, and 
DQB I *0602. 
Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune 
disease of unknown etiology. Since the first reports 
from Waters and co-workers and Grumet and co-work- 
ers in 1971, several authors have found an association 
between susceptibility to SLE and different alleles of 
the human major histocompatibility complex (HLA). 
However, the gene or genes responsible for the primary 
association have not yet been identified. The gene en- 
coding tumor necrosis factor beta (TNFB) is located in 
tandem with the tumor necrosis factor alpha gene 
within the HLA complex, between the HLA-B and C4A 
genes (Nedospasov etal. 1986). TNF-[3 is a lymphokine 
which plays an important role in the regulation of the 
immune response as part of the cytokine network 
(Goeddel et al. 1986). Because of its localization and 
the function of its product, we considered the TNFB 
gene as a candidate for the primary association with 
susceptibility oSLE. 
An Nco I polymorphic restriction site in the first 
intron of the TNFB gene (Webb et al. 1990; Messer et 
al. 1991 a; Abraham et al. 1991) allows the character- 
ization of two alleles. TNFB*I carries the Nco I restric- 
tion site, while TNFB*2 lacks it because of a point 
mutation. The aim of this study was to determine the 
frequency of Nco I-RFLP-TNFB alleles and of HLA- 
TNFB haplotypes in the healthy population and to com- 
pare them with those of the SLE patients. We also 
investigated linkage disequilibria between TNFB and 
class I or class II alleles in the healthy population. 
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Fig. 1. Segregation pattern of HLA class I
(-A and -B), class II (-DR and -DQ) and 
TNFB alleles in two panel families. Sepa- 
ration by gel electrophoresis of the frag- 
ments obtained after PCR amplification 
of a 740 bp segment of the TNFB gene 
and digestion with Nco I. Each lane corre- 
sponds to the individual shown immedi- 
ately above. TNFB*I homozygotes show 
two bands of 555 and 185 bp, respec- 
tively; TNFB*2 homozygotes, one band 
of 740 bp. In heterozygotes the three 
bands are present. JB is a TNFB*I ho- 
mozygous cell line and MW is the molec- 
ular weight marker q~ x 174/Hae III. 
Materials and methods 
Patients. The study encompassed 173 SLE German patients whose 
diagnosis fulfilled the revised American Rheumatism Association 
(ARA) criteria for SLE (Tan et al. 1982). The patients were a 
randomly selected subset of the 417 involved in the German multi- 
center SLE study (Hartung et al. 1989). They were serologically 
typed for the class I MHC loci HI_A-A, B, and C and for the class II 
loci HLA-DR and -DQ (Hartung et al. 1991). In the class III region 
they were tested for the complement loci C4A and C4B at the DNA 
level (P. Schneider, personal communication). 
Controls. One-hundred-and-ninety-two unrelated healthy individu- 
als were included as control group. Eleven panel families were also 
studied. These samples are part of the panel of the Immunogenetics 
Laboratory in Munich. They were serologically typed for class I 
antigens, RFLP typed for class II (Andreas et al. 1989) and for C4A 
and C4B (Keller et al. 1991), and using polymerase chain reaction 
(PCR)/oligonucleotide probes for DRB1, DQA1, DQB1, and DPB1. 
Determination of the Nco I-polymorphism of the TNFB gene. 
Genomic DNA was obtained from peripheral blood using a salting 
out method (Miller et al. 1988). The typing was achieved by applying 
a PCR/RFLP protocol described by Messer and co-workers (1991 b). 
Briefly, a 740 base pair (bp) fragment of the TNFB gene, which 
extends from exon 1 to intron 3 and includes the polymorphic Nco I 
restriction site, was amplified using PCR. The primers used were: 
TNF-~ L: 5' CCG TGC TTC GTG CTT TGG ACT A 3' and TNF- 
13 R: 5' AGA GCT GGT GGG GAC ATG TCT G 3'. The amplifica- 
tion product was digested with the restriction enzyme Nco I. The 
fragments obtained after amplification and digestion were detected 
by performing an electrophoresis in an agarose gel and staining with 
the fluorescent dye ethidium bromide. 
Statistical methods. Fisher's exact est was used for the comparison 
of phenotype and genotype frequencies between patients and con- 
trols. The relative risk was calculated by Woolf's method with 
Haldane's modification. Haplotype frequencies for two-locus haplo- 
types were estimated from the phenotype of random individuals by 
an iterative statistical method (Arnold and Albert 1978) using a 
computer program developed by Baur and Danilovs (1980). 
Results 
Digestion with Nco I of the amplificate obtained from 
the TNFB*I allele yielded two fragments of 555 and 
185 bp, respectively. In the case of TNFB*2 the 
amplificate suffered no change. 
Typing of panel families. Eleven panel families, typed 
serologically for HLA class I and by RFLP as well as by 
PCR/oligonucleotide probes for HLA class II, were 
tested for polymorphism ofthe TNFB gene. The pattern 
of segregation obtained in the families studied coin- 
cided with the hypothesis of a diallelic system. Further- 
more, the three possible phenotypes (TNFB*I homozy- 
gote, TNFB*2 homozygote, and the heterozygote) 
could be clearly distinguished. No problems of partial 
digestion, which could lead to false heterozygote as- 
signment, were found. Figure 1 shows the results ob- 
tained in two families. 
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Table 1. Phenotype and gene frequencies of TNFB alleles in patients and controls. 
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Allele Patients Controls p * Relative 
risk 
Phenotype frequencies 
TNFB* 1 110/173 63.6% 90/191 47.1% <0.002 1.96 
TNFB*2 147/173 85.0% 170/191 89.0% ns 0.70 
Gene frequencies 
TNFB*I 136/346 0.393 111/382 0.291 <0.004 1.6 
TNFB*2 210/346 0.607 271/382 0.709 <0.004 0.6 
* p is the two-sided probability from Fisher's exact est. 
Table 2. Two-point-haplotype analysis of HLA alleles associated with susceptibility oSLE*. 
HLA-AI HLA-Cw 7 HLA-B8 TNFB* I HLA-DR3 HLA-DQ2 
HLA- Patients = > 1637 1726 1854 1602 1750 
A1 761 1232 901 981 837 
0.49 0.71 0.62 0.53 0.52 
42.1 :I: 183.8:t: 31.0 :~ 89.5 =1: 50.5 
Controls 
HLA- 761 Patients = > 1857 2489 1849 1755 
Cw7 439 1073 884 723 473 
0.38 0.73 0.39 0.46 0.21 
11.8 + 90.5 =~ 18.6 =~ 34.1 + 10.9 =~ 
Controls 1l 
HLA- 664 783 Patients = > 2253 2005 2028 
B8 525 596 1345 1389 1187 
0.67 0.89 0.95 0.81 0.79 
46.9 :t= 34.8 + 72.5 ~: 193.1 + 107.8 :# 
Controls 
TNFB* 1 649 814 867 Patients = > 2218 2209 
208 171 601 1195 851 
0.19 0.11 0.93 0.76 0.42 
3.0 1.1 38.5 ~= 48.9 =# 18.9 ~= 
Controls ~[ 
HLA- 476 521 592 942 Patients = > 2625 
DR3 301 253 483 594 1664 
0.30 0.25 0.59 0.70 0.96 
12.5 + 4.5 + 48.5 :t= 30.4 + 193.7 
Controls ~[ 
HLA- 579 816 667 852 1071 
DQ2 258 307 468 304 830 
0.24 0.19 0.71 0.39 0.94 
5.4 3.8 27.2 + 14.9 :t= 72.6 + 
* For each two-point haplotype the table contains ablock of four figures as follows: 
1) Haplotype frequency per 10000. 
2) Absolute delta value per 10 000. 
3) Relative delta value. 
4) Chi square, 
Symbols following the Chi square value indicate the nominal level of significance: 
t = p <0.05 
t = p <0.005 
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Tab le  3. Restricted analysis of TNFB* I in comparison with HLA-A1, -Cw7, -B8, -DR3, -DQw2, and C4ADE. 
Phenotype Patients Controls Odds ratio p* 
HLA-A 1 TNFB* 1 
+ + 62 30 + + vs - -  3.1 <104 
+ - 8 21 + - vs - - ns 
- + 47  55  - + vs  - - ns 
- - 52  78 
-Cw7 TNFB*I 
+ + 71 26 + + vs - - 5.7 <10 -7 
+ - 22 22 + - vs - -  ns 
- + 19  52  - + vs  - - ns 
- - 32 67 
-B8 TNFB * I 
+ + 70 29 + + vs - - 3.9 <10- 6
+ - 1 1 + - vs - - ns 
- + 38  58  - + vs  - - ns 
- - 60 96 
C4A DE TNFB* I
+ + 36 27 + + vs - - 3.8 <10- 3
+ - 0 2 + - vs - - ns 
- + 26 44 - + vs  - - ns 
- - 26 74 
-DR3 7NFB* I
+ + 64 35 + + vs - - 3.4 <10 -5 
+ - 7 7 + - vs - - ns 
- + 35  54  - + vs  - - ns 
- - 50  92 
-DQw2 TNFB* I
+ + 72 42 + + vs - - 3.6 <10- 5
+ - 26 36 + - vs - - ns 
- + 26 39 - + vs  - - ns 
- - 32  68  
* p is the two-sided probability from Fisher's exact est. 
Phenotype frequencies. The phenotype and gene 
f requencies  of  the TNFB alleles are l isted in Table  1. 
TNFB*I is s igni f icant ly more  f requent  in patients than 
in controls (63.6% in patients and 47.1% in controls;  
p <0.002). The relat ive risk, which gives a measure  o f  
the strength of  the disease associat ion, i s  1.96. The 
phenotype f requency of  the TNFB*2 al lele is not signif-  
icantly di f ferent between both groups (85% in patients 
vs 89% in controls).  
Restricted analysis of associated alleles. There is an 
associat ion o f  susceptibi l i ty to SLE  with di f ferent 
genes of  the MHC in the group of  patients studied: 
HLA-A1, B8, Cw7, DR3, DR2, DQ2, and C4A DE. 
(Hartung et al. 1992). TNFB*I must be now added to 
this list. There  is a strong l inkage d isequi l ibr ium be- 
tween HLA-A1, B8, Cw7, DR3, DQ2, and C4A DE 
(Baur and Dan i lovs  1980). TNFB*I is also in l inkage 
d isequi l ibr ium with these alleles, as is shown by the 
results of  the two-po int  haplotype statistical analysis 
summar ized  in Table 2. In order to establ ish whether  
TNFB*I is the gene pr imar i ly  invo lved  in the suscepti-  
bi l i ty to SLE,  we analyzed the combined  presence of  
each of  the ment ioned  al leles and TNFB*I in patients 
and controls. As shown in Table  3, TNFB*I is signif i -  
cantly increased in patients compared  to controls only 
in the presence o f  the other al leles which  are part of  the 
haplotype A1, Cw7, B8, TNFB*I, C4A DE, DR3, and 
DQ2. 
Two-point haplotypes between TNFB and HLA alleles 
in the healthy German population. Two- locus  associa-  
t ions were analyzed in 192 unrelated healthy controls 
for TNFB alleles and class I antigens typed by sero logy 
and for TNFB and class II al leles typed by 
PCR/o l igonuc leot ide  probes. Table  4 summar izes  the 
statistical ly s ignif icant associat ions for class I and 
class II, respect ively.  
D i s c u s s i o n  
We have found that TNFB*I is s igni f icant ly increased 
in SLE  patients, as has been already descr ibed by Fug-  
M. P. Bettinotti et al. TNFB polymorphism in SLE 
Table 4. Linkage disequilibrium between TNFB and HLA class I and class II alleles. 
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TNFB*I TNFB*2 















670 328 0.40 9.0' 428 -328 0.40 9.0+ 
81 -330 -0.80 7.6* 1322 330 0.80 7.6 + 
881 608 0.92 36.8* 50 -608 4).92 36.8* 
38 -325 -0.89 8.5t 1184 325 0.89 8.5t 
845 547 0.78 28.7 * 155 -547 4).78 28.7 * 
261 170 0.79 8.4t 44 - 170 4).79 8.4t 
426 228 0.49 7.2' 241 -228 4).49 7.2t 
1251 518 0.30 12.5 + 1207 -518 4).30 12.5* 
982 434 0.32 10.8t 925 -434 4).32 10.8t 
123 -250 4).67 4.9* 1175 250 0.67 4.9* 
298 155 0.44 4.5* 199 -155 4).44 4.5* 
320 194 0.64 8.3* 108 -194 4).64 8.3t 
f is the haplotype frequency per 10000; A is the absolute delta value per 10000; Ar is the relative delta value and Z2, 
following the Chi square value indicate the nominal level of significance: 
* = p <0.05; t - p <0.01; * = p <0.005. 
Chi square. Symbols 
get and co-workers (1989) in a small group of patients. 
Messer and co-workers (1991 a) have reported that 
there is not only a structural but also a functional differ- 
ence between both TNFB alleles. Upon stimulation 
with phytohemagglut inen (PHA) of peripheral b lood 
mononuclear (PBMN) cells in vitro, TNFB*I homozy-  
gotes are higher responders than TNFB*2 homozy-  
gotes. This, coupled with the fact that the TNFB gene is 
on the MHC, could explain the association of the MHC 
with SLE. 
However,  coinciding with previous reports from 
Dawkins and co-workers (1989), Badenhoop and co- 
workers (1989), and Fugger and co-workers (1989), we 
have found that the l inkage disequi l ibr ium of the A1, 
B8, C4A DE, DR3, and DQ2 haplotype also includes 
the TNFB*I allele. TNFB*I is signif icantly increased 
in patients only as part of  this haplotype. It is not 
possible to determine which gene (or genes) carried by 
this haplotype is (or are) pr imari ly responsible for con- 
ferring susceptibi l i ty to SLE. 
Final ly, the analysis of the two-locus haplotypes in 
the control individuals rendered the fol lowing results: 
TNFB*I is associated with different alleles which 
can be grouped into three common Caucasian haplo- 
types: 
1. HLA-B8, DRBI*0301, DQAI*0501, 
DQBI*0201, and DPBI*OIO1. 
2. DRBI* l l04  and DQAI*0501. 
3. DRB 1.1302 and DQBI*0604. 
TNFB*2 is associated with HLA-B7, DRBI*1501, 
and DQBI*0602, which are also part of a common 
Caucasian haplotype. 
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